<DOC>
	<DOCNO>NCT00374543</DOCNO>
	<brief_summary>This study propose examine potential safety efficacy ziprasidone patient anxiety bipolar disorder anxiety outcome , bipolar symptom , measure quality life resilience .</brief_summary>
	<brief_title>Ziprasidone Treatment Generalized Anxiety Patients With Bipolar Disorder</brief_title>
	<detailed_description>This study would first prospective , placebo-controlled study knowledge pharmacotherapy strategy treatment comorbid generalize anxiety ( comorbid anxiety ) patient bipolar disorder . Our hypothesis : 1 . Ziprasidone flexibly dose 40 160 mg/day reduce anxiety symptom significantly placebo patient bipolar disorder full subsyndromal diagnosis generalize anxiety disorder ( GAD ) . 2 . Ziprasidone well tolerated patient generalize anxiety base incidence treatment emergent adverse effect 8 week therapy , base lack worsen bipolar depression , mania hypomania compare placebo . 3 . Treatment ziprasidone significantly great positive impact measure quality life resilience placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Male female outpatient , age 18 75 year . Diagnosis Bipolar Disorder ( Bipolar I Bipolar II ) . Current diagnosis Generalized Anxiety Disorder ( GAD ) . Participants must least one follow mood stabilizer steady dose least 4 week prior randomization : lithium blood level 0.41.4 meq/L , valproic acid/divalproate sodium ( level 50150 ugm/dl ) carbamazepine ( blood level 412 mcg/ml ) , lamotrigine ( dosed 50400 mg/day ) . Pregnant lactate woman others use acceptable mean birth control ( e.g. , IUD , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . Patients current history schizophrenia , patient current mania , hypomania study entry . Lifetime psychosis dementia exclusionary . Patients current obsessivecompulsive disorder posttraumatic stress disorder exclude . Patients history alcohol substance abuse dependence within last three month . Patients significant unstable medical illness likely result hospitalization acute medical care . In addition , patient establish diagnosis diabetes mellitus exclude . Current cognitive behavioral therapy direct toward treatment generalize anxiety disorder . History hypersensitivity lack response ziprasidone . Concomitant treatment typical atypical antipsychotic ; patient typical atypical antipsychotic least one week prior study baseline . Patients significant suicidal ideation enact suicidal behavior within 3 month prior intake exclude study participation refer appropriate clinical intervention . Patients psychiatric hospitalization ( include bipolar disorder ) past 3 month exclude . Seizure disorder exception history febrile seizure occur childhood , isolate , recur adulthood . History Neuroleptic Malignant Syndrome . Individuals current clinically significant orthostatic hypotension exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Ziprasidone</keyword>
</DOC>